Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements


Original Research 
RMJ. 2021; 46(4): 761-764


Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease

Kashif Rasheed Shaikh, Shumaila Shaikh, Muhammad Atif Ata, Azhar Memon, Umair Ali Soomro, Shumail Saeed Siddiqui.

Abstract
Objective: To determine the therapeutic efficacy of silymarin on liver aminotransferases in non-alcoholic fatty liver disease (NAFLD).
Methodology: This case control study was carried out at Suleman Roshan Medical College from August 2019 to March 2020. A sample of 200 diagnosed cases of NAFLD was divided into 2 groups; cases received 2 tablets silymarin (200 mg) per day for 12 weeks and controls received placebo. Baseline and after 12 weeks blood samples were taken for the liver aminotransferase measurements. Data were analyzed on SPSS version 21.0.
Results: Frequency of fatty liver disease at baseline in cases and controls was noted as: grade 1- 32% vs. 31%, grade 2 - 60% vs. 61% and grade 3- 8% vs. 7% (p=0.91. ALT in cases decreased from 89.77.31 to 67.33.9 IU/mL and AST decreased from 72.35.9 to 53.95.7 IU/mL while ALT in controls decreased from 88.98.1 to 79.37.1 and AST from 71.35.3 to 70.96.13 (p=0.0001).
Conclusion: Silymarin therapy effectively improved NAFLD with improvement of liver aminotransferases.

Key words: Silylmarin, NAFLD, sonography, ALT, AST.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Kashif Rasheed Shaikh
Articles by Shumaila Shaikh
Articles by Muhammad Atif Ata
Articles by Azhar Memon
Articles by Umair Ali Soomro
Articles by Shumail Saeed Siddiqui
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Shaikh KR, Shaikh S, Ata MA, Memon A, Soomro UA, Siddiqui SS. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease.


Web Style

Shaikh KR, Shaikh S, Ata MA, Memon A, Soomro UA, Siddiqui SS. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease. http://www.rmj.org.pk/?mno=34092 [Access: October 13, 2021].


AMA (American Medical Association) Style

Shaikh KR, Shaikh S, Ata MA, Memon A, Soomro UA, Siddiqui SS. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease.



Vancouver/ICMJE Style

Shaikh KR, Shaikh S, Ata MA, Memon A, Soomro UA, Siddiqui SS. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease.



Harvard Style

Shaikh, K. R., Shaikh, . S., Ata, . M. A., Memon, . A., Soomro, . U. A. & Siddiqui, . S. S. (2021) Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease.



Turabian Style

Shaikh, Kashif Rasheed, Shumaila Shaikh, Muhammad Atif Ata, Azhar Memon, Umair Ali Soomro, and Shumail Saeed Siddiqui. 2021. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease.



Chicago Style

Shaikh, Kashif Rasheed, Shumaila Shaikh, Muhammad Atif Ata, Azhar Memon, Umair Ali Soomro, and Shumail Saeed Siddiqui. "Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease."



MLA (The Modern Language Association) Style

Shaikh, Kashif Rasheed, Shumaila Shaikh, Muhammad Atif Ata, Azhar Memon, Umair Ali Soomro, and Shumail Saeed Siddiqui. "Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease."



APA (American Psychological Association) Style

Shaikh, K. R., Shaikh, . S., Ata, . M. A., Memon, . A., Soomro, . U. A. & Siddiqui, . S. S. (2021) Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease.








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED,  Scopus and Web of Science

                     Approved by the Higher Education Commission of Pakistan 


ABOUT JOURNAL
POLICIES
STATEMENTS

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.